BRIEF-Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo

Reuters01-12 06:16

BRIEF-<a href="https://laohu8.com/S/TEVA">Teva</a> And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo

Jan 11 (Reuters) - Royalty Pharma PLC RPRX.O:

TEVA AND ROYALTY PHARMA ENTER AGREEMENT TO ACCELERATE DEVELOPMENT OF POTENTIAL TREATMENT FOR VITILIGO
TEVA - TEVA TO SHARE TEV-'408 TRIAL RESULTS IN 2026
ROYALTY PHARMA - TO PROVIDE UP TO $500 MILLION FOR TEVA'S TEV-'408
ROYALTY PHARMA : TEV-'408 IS CURRENTLY IN PHASE 1B FOR TREATMENT OF VITILIGO AND IN PHASE 2A FOR CELIAC DISEASE

Source text: ID:nGNXbWXSwh

Further company coverage: RPRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602568024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 06:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602568024","market":"nz","top_or_hot":-1,"title":"BRIEF-Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TEVA\">Teva</a> And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span>Royalty Pharma <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>RPRX.O</span>:</p><ul><li><p>TEVA AND ROYALTY PHARMA ENTER AGREEMENT TO ACCELERATE DEVELOPMENT OF POTENTIAL TREATMENT FOR VITILIGO</p></li><li><p>TEVA - TEVA TO SHARE TEV-'408 TRIAL RESULTS IN 2026</p></li><li><p>ROYALTY PHARMA  - TO PROVIDE UP TO $500 MILLION FOR TEVA'S TEV-'408</p></li><li><p>ROYALTY PHARMA : TEV-'408 IS CURRENTLY IN PHASE 1B FOR TREATMENT OF VITILIGO AND IN PHASE 2A FOR CELIAC DISEASE</p></li></ul><p>Source text: <span>ID:nGNXbWXSwh</span></p><p>Further company coverage: <span>RPRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 06:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/TEVA\">Teva</a> And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span>Royalty Pharma <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>RPRX.O</span>:</p><ul><li><p>TEVA AND ROYALTY PHARMA ENTER AGREEMENT TO ACCELERATE DEVELOPMENT OF POTENTIAL TREATMENT FOR VITILIGO</p></li><li><p>TEVA - TEVA TO SHARE TEV-'408 TRIAL RESULTS IN 2026</p></li><li><p>ROYALTY PHARMA  - TO PROVIDE UP TO $500 MILLION FOR TEVA'S TEV-'408</p></li><li><p>ROYALTY PHARMA : TEV-'408 IS CURRENTLY IN PHASE 1B FOR TREATMENT OF VITILIGO AND IN PHASE 2A FOR CELIAC DISEASE</p></li></ul><p>Source text: <span>ID:nGNXbWXSwh</span></p><p>Further company coverage: <span>RPRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nFWN3YA0ZI:1","article_id":"2602568024","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602568024","pubTimestamp":1768169770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For VitiligoJan 11 (Reuters) - Royalty Pharma PLC RPRX.O:TEVA AND ROYALTY PHARMA ENTER AGREEMENT TO ACCEL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RPRX":"Royalty Pharma plc"},"translate_title":"简介-梯瓦(Teva)和Royalty Pharma达成协议，加速白癜风潜在治疗方法的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":0.9},"content_text":"BRIEF-Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For VitiligoJan 11 (Reuters) - Royalty Pharma PLC RPRX.O:TEVA AND ROYALTY PHARMA ENTER AGREEMENT TO ACCELERATE DEVELOPMENT OF POTENTIAL TREATMENT FOR VITILIGOTEVA - TEVA TO SHARE TEV-'408 TRIAL RESULTS IN 2026ROYALTY PHARMA  - TO PROVIDE UP TO $500 MILLION FOR TEVA'S TEV-'408ROYALTY PHARMA : TEV-'408 IS CURRENTLY IN PHASE 1B FOR TREATMENT OF VITILIGO AND IN PHASE 2A FOR CELIAC DISEASESource text: ID:nGNXbWXSwhFurther company coverage: RPRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602568024","isCrawlerRequest":true}